Drugmakers to pay for TV ad reviews under FDA plan

  1. WASHINGTON (Reuters) - Drugmakers would have to pay $6.25 million in new fees next year to help fund a U.S. Food and Drug Administration review of television commercials for their products the agency said on Thursday.

    The advertising plan accompanies an agreement for proposed legislation to renew industry funding for FDA drug reviews through 2012. The FDA also receives money from the federal budget.